Drew Moghanaki: A New Publication Shows SBRT Is More Cost-Effective for Stage I NSCLC
Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X about a paper by Andrew Kennedy et al. published in Radiation Oncology:
“A new publication shows SBRT is more cost-effective, with a greater improvement in quality of life than surgery for stage I NSCLC. As usual, there are caveats with the analyses.”
Title: A prospective outcomes and cost-effective analysis of surgery compared to stereotactic body radiation therapy for stage I non-small cell lung cancer
Authors: Andrew Kennedy, Shanna A. Arnold Egloff, Casey Martin, Denis Gilmore, Susan Garwood, Tammy Baxter, David Spigel, Melissa Johnson, David Randolph II, Casey Chollet-Lipscomb, Laurie Cuttino, Eleanor Osborne, Jenifer Marks, Pratik Doshi, Meredith Mattlin, Richard Geer, Dax Kurbegov, Howard Burris III
You can read the Full Article in Radiation Oncology.
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023